While Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have appreciated 38 percent since the favorable U.S. Fanapt IP ruling on August 25, Jefferies’ Matthew J. Andrews believes that there could be potential for long-term upside to the...
CANONSBURG (dpa-AFX) - Chembio Diagnostics Inc. (CEMI) has been awarded up
to $13.2 million U.S. Government contract for the development and
commercialization of the company's rapid POC Zika test and Zika-related
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) revealed that the U.S. Food and Drug Administration has granted three years of marketing exclusivity for the changes in respect of the supplemental New Drug Application (sNDA), which was recently approved...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Vanda Pharmaceuticals (VNDA):